The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites.
breast cancer
epithelial mesenchymal transition
extracellular vesicle
fibroblast
fibronectin
metastasis
plasticity
premetastatic niche
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 May 2020
17 May 2020
Historique:
received:
17
04
2020
revised:
09
05
2020
accepted:
15
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
In breast cancer (BC), tissue stiffening via fibronectin (FN) and collagen accumulation is associated with advanced disease progression at both the primary tumor and metastatic sites. Here, we evaluate FN production in 15 BC cell lines, representing a variety of subtypes, phenotypes, metastatic potentials, and chemotherapeutic sensitivities. We demonstrate that intracellular and soluble FN is initially lost during tumorigenic transformation but is rescued in all lines with epithelial-mesenchymal plasticity (EMP). Importantly, we establish that no BC cell line was able to independently organize a robust FN matrix. Non-transformed mammary epithelial cells were also unable to deposit FN matrices unless transglutaminase 2, a FN crosslinking enzyme, was overexpressed. Instead, BC cells manipulated the FN matrix production of fibroblasts in a phenotypic-dependent manner. In addition, varied accumulation levels were seen depending if the fibroblasts were conditioned to model paracrine signaling or endocrine signaling of the metastatic niche. In the former, fibroblasts conditioned by BC cultures with high EMP resulted in the largest FN matrix accumulation. In contrast, mesenchymal BC cells produced extracellular vesicles (EV) that resulted in the highest levels of matrix formation by conditioned fibroblasts. Overall, we demonstrate a dynamic relationship between tumor and stromal cells within the tumor microenvironment, in which the levels and fibrillarization of FN in the extracellular matrix are modulated during the particular stages of disease progression.
Identifiants
pubmed: 32429591
pii: cancers12051270
doi: 10.3390/cancers12051270
pmc: PMC7281295
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : UL1TR002529
Pays : United States
Organisme : NIH HHS
ID : DP2 AT009833
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA198929
Pays : United States
Organisme : NCCIH NIH HHS
ID : DP2 AT009833
Pays : United States
Organisme : NCI NIH HHS
ID : R00CA198929
Pays : United States
Références
Clin Exp Metastasis. 1993 Jan;11(1):103-12
pubmed: 8422701
Cancer Metastasis Rev. 2016 Dec;35(4):669-676
pubmed: 27838868
Mol Cancer Res. 2018 Oct;16(10):1579-1589
pubmed: 29934326
Cells. 2019 Dec 20;9(1):
pubmed: 31861892
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Acta Pharm Sin B. 2015 Sep;5(5):402-18
pubmed: 26579471
Mol Cancer. 2019 Dec 3;18(1):175
pubmed: 31796058
BMC Cancer. 2008 Aug 09;8:228
pubmed: 18691423
Oncotarget. 2016 Dec 13;7(50):83424-83436
pubmed: 27825137
Matrix Biol. 2017 Jul;60-61:86-95
pubmed: 27503584
Biomed Res Int. 2019 Jul 2;2019:4649705
pubmed: 31355262
Am J Pathol. 2011 Jan;178(1):325-35
pubmed: 21224069
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Oncotarget. 2016 Feb 9;7(6):7066-79
pubmed: 26771235
Nature. 2016 Dec 22;540(7634):588-592
pubmed: 27974798
Elife. 2019 May 30;8:
pubmed: 31144616
Breast Dis. 2010;32(1-2):35-48
pubmed: 21778573
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
Breast Cancer Res Treat. 2000 Dec;64(3):235-40
pubmed: 11200773
Mol Carcinog. 2020 Mar;59(3):323-332
pubmed: 31943365
J Oral Biol Craniofac Res. 2018 May-Aug;8(2):122-125
pubmed: 29892534
Cancers (Basel). 2020 Jan 10;12(1):
pubmed: 31936750
Am J Physiol Renal Physiol. 2008 Jul;295(1):F153-64
pubmed: 18434385
Front Oncol. 2018 Sep 12;8:381
pubmed: 30258818
Adv Anat Pathol. 2019 Jan;26(1):69-74
pubmed: 30339548
Cancer Cell. 2009 Jan 6;15(1):35-44
pubmed: 19111879
Mol Biol Cell. 2017 May 1;28(9):1195-1207
pubmed: 28298487
Mol Cancer. 2019 Mar 11;18(1):39
pubmed: 30857545
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Cancer Metastasis Rev. 2012 Dec;31(3-4):429-40
pubmed: 22699312
J Vis Exp. 2016 Dec 31;(118):
pubmed: 28117772
Cancer Res. 2019 Apr 15;79(8):1831-1843
pubmed: 30733195
Breast Cancer Res Treat. 2001 Jan;65(2):101-10
pubmed: 11261825
J Biol Eng. 2019 May 22;13:43
pubmed: 31139251
Curr Opin Cell Biol. 2015 Oct;36:13-22
pubmed: 26183445
Annu Rev Cell Dev Biol. 2010;26:397-419
pubmed: 20690820
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
J Biol Chem. 2013 Jun 21;288(25):17954-67
pubmed: 23653350
Cancer Med. 2019 Sep;8(12):5574-5576
pubmed: 31397113
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3502-3507
pubmed: 30755531
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Exp Ther Med. 2018 Sep;16(3):1567-1576
pubmed: 30186373
Oncogenesis. 2020 Feb 13;9(2):16
pubmed: 32054828
J Cell Biol. 1983 Aug;97(2):466-72
pubmed: 6309861
Sci Rep. 2016 Aug 30;6:32377
pubmed: 27572480
Adv Drug Deliv Rev. 2016 Feb 1;97:41-55
pubmed: 26743193
Breast Cancer Res. 2009;11(5):R68
pubmed: 19740433
Cancer Res. 2006 Dec 1;66(23):11089-93
pubmed: 17145848
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Adv Mater. 2019 Nov;31(46):e1904580
pubmed: 31565823
Curr Opin Cell Biol. 2008 Oct;20(5):495-501
pubmed: 18640274
Front Physiol. 2018 Jun 05;9:651
pubmed: 29922170